{"entity":{"id":"nct06120140","kind":"trial","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","aka":["COCOON"],"tldr":"A phase 2 trial of Amivantamab and Lazertinib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib is a phase 2 interventional study registered as NCT06120140 by Janssen Research & Development, LLC, with 305 participants enrolled, started 2024-02-16 and due to reach its primary completion in 2027-05-31. Interventions recorded: Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline and Clindamycin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06120140","url":"https://clinicaltrials.gov/study/NCT06120140"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":["bispecific-antibody","kinase-inhibitors"],"targets":[],"drugs":["amivantamab","lazertinib"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct06120140-j-thorac-oncol-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06120140","phase":"2","setting":"A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib","sponsor":"Janssen Research & Development, LLC","started":"2024-02-16","startedType":"actual","enrolled":305,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06120140/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}],"paper":[{"id":"paper-nct06120140-j-thorac-oncol-2025","kind":"paper","name":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","route":"/key-papers/paper-nct06120140-j-thorac-oncol-2025/"}]}}